תאריך רישום: December 28, 2016

מסלול הגשה: תכשיר גנרי

יצרן: FRESENIUS KABI NORGE AS, NORWAY

בעל רישום: CURE MEDICAL & TECHNICAL SUPPLY

B05XA31 :ATC Code

4.1 Therapeutic indications To meet basal to moderately increased requirements of trace elements in intravenous nutrition.

תאריך רישום: September 4, 2017

מסלול הגשה: מולקולה חדשה

יצרן: UNIMEDIC AB, SWEDEN

בעל רישום: MEDISON PHARMA LTD

A16AX09 :ATC Code

4.1 Therapeutic indications RAVICTI is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

תאריך רישום: June 2, 2018

מסלול הגשה: מולקולה חדשה

יצרן: PATHEON INC., CANADA

בעל רישום: NEOPHARM LTD, ISRAEL

L01XX55 :ATC Code

1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

תאריך רישום: June 2, 2018

מסלול הגשה: מולקולה חדשה

יצרן: PATHEON INC., CANADA

בעל רישום: NEOPHARM LTD, ISRAEL

L01XX55 :ATC Code

1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

תאריך רישום: April 13, 1994

מסלול הגשה: מולקולה חדשה

יצרן: PADAGIS ISRAEL PHARMACEUTICALS LTD, ISRAEL

בעל רישום: PADAGIS ISRAEL PHARMACEUTICALS LTD, ISRAEL

M02AA07 :ATC Code

4.1. Therapeutic Indications Exipan Gel is a non-steroidal anti-inflammatory agent. For local treatment of inflammatory conditions accompanied by pain.

תאריך רישום: June 2, 2018

מסלול הגשה: מולקולה חדשה

יצרן: PATHEON INC., CANADA

בעל רישום: NEOPHARM LTD, ISRAEL

L01XX55 :ATC Code

1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy